- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02884492
Imaging Tau in Alzheimer's Disease and Normal Aging
November 14, 2018 updated by: William Charles Kreisl
This study is being done to learn about tau tangles in Alzheimer's disease.
A type of PET scan is used to measure the abnormal accumulation of protein called tau in the brain.
These are thought to be involved in Alzheimer's disease.
The investigators will also perform brain MRI and to tests to measure the participant's memory and thinking.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This study is being done to determine the relationship between tau tangles and cognitive impairment in elderly subjects with different clinical and biomarker profiles of Alzheimer's disease (AD).
Subjects will undergo screen that includes neuropsychological testing and brain MRI.
This study uses a special type of scan called a PET scan to take pictures of the brain.
During the PET scan, a special radioactive dye called 18F-THK-5351 is injected into the body.
18F-THK-5351 sticks to abnormal tangles made of the protein tau.
Subjects will have the option to have lumbar puncture performed to measure CSF concentrations of biomarkers.
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 50 and older.
- Meet criteria for either a) amnestic mild cognitive impairment (single or mixed domain) or mild Alzheimer's disease, or b) have no cognitive impairment, based on history, exam, neuropsychological testing, and consensus diagnosis. MCI and mild AD patients must have Clinical Dementia Rating scale score of 0.5 or 1. Unimpaired subjects must have Clinical Dementia Rating scale score of 0.
- Subjects unable to provide informed consent must have a surrogate decision maker.
- Written and oral fluency in English or Spanish.
- Able to participate in all scheduled evaluations and to complete all required tests and procedures.
- In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.
Exclusion Criteria:
- Past or present history of certain brain disorders other than MCI or AD.
- Certain significant medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.
- Contraindication to MRI scanning.
- Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).
- History of kidney disease or presence of impaired kidney function based on laboratory tests at the screening visit.
- History of liver disease or presence of impaired liver function based on laboratory tests at the screening visit.
- Participation in the last year in a clinical trial for a disease-modifying drug for AD.
- Inability to have a catheter in subject's vein for the injection of radioligand.
- Inability to have blood drawn from subject's veins.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive impairment
Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
|
Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau.
These tau tangles develop in the brain in people with Alzheimer's disease.
Other Names:
|
Active Comparator: No cognitive impairment
Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
|
Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau.
These tau tangles develop in the brain in people with Alzheimer's disease.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
18F-THK-5351 Standardized Uptake Value Ratio
Time Frame: PET image data collected 50 min post-injection to 70 min post-injection of 18F-THK-5351
|
The standardize uptake value ratio is the concentration of radioactivity measured from the 18F-THK-5351 PET scan in the posterior cingulate gyrus, divided by that in the cerebellar gray matter (the reference region, which is expected to be devoid of tau pathology).
This ratio is a relative measure of 18F-THK-5351 binding, and therefore of tau pathology, in brain tissue.
PET image data was acquired from 50 min post-injection to 70 min post-injection of 18F-THK-5351.
|
PET image data collected 50 min post-injection to 70 min post-injection of 18F-THK-5351
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: William C Kreisl, MD, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Actual)
June 30, 2017
Study Completion (Actual)
June 30, 2017
Study Registration Dates
First Submitted
August 25, 2016
First Submitted That Met QC Criteria
August 25, 2016
First Posted (Estimate)
August 31, 2016
Study Record Updates
Last Update Posted (Actual)
November 19, 2018
Last Update Submitted That Met QC Criteria
November 14, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAQ7868
- 1K23AG052633-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsRecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Lumbar Puncture (optional)
-
James M Noble, MD, MS, CPH, FAANNational Institute on Aging (NIA)Completed
-
Centre Hospitalier Universitaire DijonNovartis PharmaceuticalsRecruitingMegalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)France
-
National Institute of Allergy and Infectious Diseases...Novartis Pharmaceuticals; Autoimmunity Centers of ExcellenceCompletedSecondary Progressive Multiple SclerosisUnited States
-
Wake Forest University Health SciencesRecruiting
-
University of NebraskaUnknownIndication for Lumbar PunctureUnited States
-
Dartmouth-Hitchcock Medical CenterTerminated
-
IRCCS San RaffaeleTeresa Calimeri; Sara SteffanoniRecruiting
-
Universitair Ziekenhuis BrusselRecruitingAlzheimer Disease | Mild Cognitive ImpairmentBelgium
-
The Netherlands Cancer InstituteCompletedMeningeal CarcinomatosisNetherlands
-
University Hospital, ToursCompleted